Bone Biologics Corporation BBLGW
Oct 12, 2026, 10:41 AM EDT
- YTD
- -58.71%
- 1 year
- -38.40%
- Market cap
- 13.83M
- EPS (ttm)
- -0.144
- YTD return
- -58.71%
- 1-year return
- -38.40%
- Volume
- 249
- Avg volume
- 990
- Open
- 9.97
- Previous close
- 7.70
- Day's range
- 5.39 – 10.67
- 52-week range
- 3.50 – 35.95
- Beta
- 0.74
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.83M
- Total cash
- 2.33M
- Total debt
- 0
- Return on equity
- -119.03%
- Short % of float
- 0.00%
- 50-day average
- 31.34
- 200-day average
- 40.77
Next earnings
Consensus EPS estimate 0.00.
About Bone Biologics Corporation
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bonebiologics.com
News
Your note
Sign in to keep a note on BBLGW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Citadel Advisors Llc | 3.87% | 36,751 | 1.02M | Sep 29, 2024 |
| UBS Group AG | 0.00% | 40 | 1.11K | Sep 29, 2024 |